Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAL1273 (bupivacaine)
- Development stage
- Preclinical
- Lead developer
- Nal Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
NAL1273 is a long-acting liposomal formulation of the local anesthetic **bupivacaine**, currently under development by **NAL Pharmaceutical Group**. Designed as a sustained-release injection, NAL1273 aims to provide extended pain relief for up to three days following administration. The drug's mechanism of action involves the blockade of **voltage-gated sodium channels** on neuronal membranes, which prevents the initiation and conduction of nerve impulses, thereby producing local anesthesia and analgesia. NAL1273 is primarily targeted for use in pain management and local anesthesia and is currently in the preclinical stage of development.
- Other names
- Bupivacaine Liposome 3-Day Injectionliposomal bupivacaine
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)CaV (Voltage-gated calcium channel protein complex)Kir (Inward-rectifier potassium channels)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on NAL1273 (bupivacaine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAL1273 (bupivacaine).